Takeda to pay $200M for rights to anemia drug from Keros
Takeda is tapping into a Boston-area biotech’s late-stage anemia drug as it looks to boost its oncology portfolio amid a quarters-long revamp …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
